期刊文献+

孕烷X受体在肾脏疾病中的研究进展 被引量:2

Research Progress of Pregnane X Receptor in Kidney Disease
原文传递
导出
摘要 核受体是一类在机体内广泛分布的转录因子,在人体生理、病理过程中发挥重要作用。孕烷X受体(pregnaneX receptor,PXR)为核受体家族成员之一,参与机体物质代谢,尤其在药物代谢中起关键作用。肾脏是药物代谢的主要器官之一,PXR参与肾脏药物代谢、转运等多种调节并参与多种肾脏疾病的病理生理过程。近年来多项研究关注PXR及其调控作用对肾脏及肾脏疾病的影响。本文将从PXR在肾脏与药物代谢和转运相关酶的相互作用以及PXR在肾脏疾病中的作用等方面进行综述。 Nuclear receptors are a group of transcription factors that widely distributed in the body and play an important role in both physiological and pathological processes.Pregnane X receptor(PXR)is a member of the nuclear receptor family,which is mainly involved in various biological activities,especially in drug metabolism.Kidney is one of the main organs that take part in the regulation of drug metabolism.PXR is involved in various regulation such as renal drug metabolism and transport,and is involved in the pathophysiological process of various kidney diseases.In recent years,researchers have focused on the effects of PXR and its regulatory functions in kidney and renal diseases.This review mainly discusses the role of PXR on renal physiology,the interaction of PXR and the drug metabolic enzymes and its functions in pathological process in renal diseases.
作者 窦景云 古月瑜 刘旭生 DOU Jingyun;GU Yueyu;LIU Xusheng(The Second Clinical College,Guangzhou University of Chinese Medicine,Guangzhou 510405,China;Department of Nephrology,The Second Affiliated Hospital,Guangzhou University of Chinese Medicine(Guangdong Provincial Hospital of Chinese Medicine),Guangzhou 510120,China)
出处 《中国现代应用药学》 CAS CSCD 北大核心 2022年第11期1503-1508,共6页 Chinese Journal of Modern Applied Pharmacy
基金 国家自然科学基金项目(81903956) 广东省中医药管理局面上项目(20201133) 广州市科技局基础与应用基础研究项目(202102020011)
关键词 孕烷X受体 肾脏疾病 药物代谢 代谢酶 综述 pregnane X receptor kidney disease drug metabolism metabolic enzymes review
  • 相关文献

参考文献4

二级参考文献25

  • 1Thiebaut F, Tsuruo T, Hamada H, Gottesman M, Pastan I, Willingham MC. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci USA 1987; 84:7735-8.
  • 2Cordon-Cardo C, O'Brien JP, Casals D, Rittman-Grauer L, Biedler JL, Melamed MR, et al. Multidrug-resistance gene (P- glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc Natl Acad Sci USA 1989; 86:695-8.
  • 3Motojima M, Nishijima F, Ikoma M, Kawamura T, Yoshioka T, Fogo AB, et al. Role for 'uremic toxin' in the progressive loss of intact nephrons in chronic renal failure. Kidney Int 1991; 40: 461-9.
  • 4Lysaght MJ, Vonesh EF, Gotch F, Ibels L, Keen M, Lindholm B, et al. The influence of dialysis treatment modality on the decline of remaining renal function. ASAIO Trans 1991; 37: 598- 604.
  • 5Rottembourg J. Residual renal function and recovery of renal function in patients treated by CAPD. Kidney Int 1993; 43: S106-10.
  • 6Sanaka T, Sugino N, Teraoka S, Ota K. Therapeutic effects of oral sorbent in undialyzed uremia. Am J Kidney Dis 1988; 12: 97-103.
  • 7Niwa T, Nomura T, Sugiyama S, Miyazaki T, Tsukushi S, Tsutsui S. The protein metabolite hypothesis, a model for the progression of renal failure: An oral adsorbent lowers indoxyl sulfate levels in undialyzed uremic patients. Kidney Int 1997; 52: S23-8.
  • 8Mickley LA, Lee JS, Weng Z, Zhan Z, Alvarez M, Wilson W, et al. Genetic polymorphism in MDR-I: a tool for examining allelic expression in normal cells, unselected and drug-selected cell lines, and human tumors. Blood 1998; 91: 1749-56.
  • 9Hoffmeyer S, Burk O, von Richter O, Arnold HE Brockmoller J, Johne A, et al. Functional polymorphisms of the human multidrugresistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 2000; 97: 3473-8.
  • 10Siegsmund M, Brinkmann U, Schaffeler E, Weirich G, Schwab M, Eichelbaum M, et al. Association of the P-glycoprotein trans- porter MDR1(C3435T) polymorphism with the susceptibility to renal epithelial tumors. J Am Soc Nephrol 2002; 13: 1847-54.

共引文献21

同被引文献57

引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部